A Phase 1 interventional study of Selpercatinib in Healthy, sponsored by Loxo Oncology, Inc.. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-21.
Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to learn about how food affects selpercatinib in healthy participants. The selpercatinib will be administered in fed and fasted states. Participation could last about 7 weeks.
Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: 160 milligrams (mg) Selpercatinib administered orally on Day 1 in fasted state. Period 2: 160 mg Selpercatinib administered orally on Day 8 in fed state.
Drug: Selpercatinib
Period 1: 160 mg Selpercatinib administered orally on Day 1 in fed state. Period 2: 160 mg Selpercatinib administered orally on Day 8 in fasted state.
Drug: Selpercatinib
Administered orally.
Also known as: LY3527723, LOXO-292
Pharmacokinetics(PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib
PK: AUC\[0-∞\] of Selpercatinib'
Time frame: PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;
PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib
PK: AUC\[0-tlast\] of Selpercatinib
Time frame: PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;
PK: Maximum Concentration (Cmax) of Selpercatinib
PK: Cmax of Selpercatinib.
Time frame: PK: Day 1 and Day 8: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, and 72 hours (h) postdose;
| Milestone | Selpercatinib Fasted/Fed | Selpercatinib Fed/Fasted |
|---|---|---|
| Started | 23 | 23 |
| Received one dose of study drug | 23 | 23 |
| Completed | 22 | 22 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | Selpercatinib Fasted/Fed | Selpercatinib Fed/Fasted |
|---|---|---|
| Started | 22 | 22 |
| Completed | 22 | 22 |
| Not completed | 0 | 0 |
PK: AUC\[0-∞\] of Selpercatinib'
| nanogram * hour per milliliter (ng*hr/mL | Selpercatinib Fasted (Reference) | Selpercatinib Fed (Test) |
|---|---|---|
| Pharmacokinetics(PK): Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib | 23400 ± 32 | 22500 ± 44 |
PK: AUC\[0-tlast\] of Selpercatinib
| ng*hr/mL | Selpercatinib Fasted (Reference) | Selpercatinib Fed (Test) |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib | 22700 ± 32 | 21700 ± 46 |
PK: Cmax of Selpercatinib.
| nanograms per milliliter (ng/mL) | Selpercatinib Fasted (Reference) | Selpercatinib Fed (Test) |
|---|---|---|
| PK: Maximum Concentration (Cmax) of Selpercatinib | 1840 ± 39 | 1540 ± 45 |
Collected over Screening up to 21 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 160 mg Selpercatinib Fasted | 0/45 (0%) | 0/45 (0%) | 29/45 (64.4%) |
| 160 mg Selpercatinib Fed | 0/45 (0%) | 0/45 (0%) | 21/45 (46.7%) |
| Event | 160 mg Selpercatinib Fasted | 160 mg Selpercatinib Fed |
|---|---|---|
| Catheter site erythemaGeneral disorders | 12/45 | 13/45 |
| Catheter site painGeneral disorders | 10/45 | 6/45 |
| DiarrhoeaGastrointestinal disorders | 7/45 | 5/45 |
| Catheter site bruiseGeneral disorders | 7/45 | 4/45 |
| HeadacheNervous system disorders | 6/45 | 1/45 |
| FatigueGeneral disorders | 4/45 | 3/45 |
| Catheter site swellingGeneral disorders | 3/45 | 3/45 |
| Vessel puncture site bruiseGeneral disorders | 3/45 | 3/45 |
All randomized participants.
| Age, Continuous(years) | Selpercatinib |
|---|---|
| Mean | 40.6 ± 9.2 |
| Sex: Female, Male(Participants) | Selpercatinib |
|---|---|
| Female | 10 |
| Male | 36 |
| Ethnicity (NIH/OMB)(Participants) | Selpercatinib |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 46 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Selpercatinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 45 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 1 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Selpercatinib |
|---|---|
| Singapore | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Jun 2022, 2 months.
Results were first posted in Mar 2025, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib